HopeStage
Back to all studies
CompletedNCT03093064

Natalizumab and Brain Inflammation in Schizophrenia

About this titleRead the official source — NCT03093064
Medication studyAges 18–50United Kingdom
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 50 years.

Listed locations
LondonSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: April 1, 2017
Recruitment status
Completed
Enrollment listed in the registry
66
Sponsor
King's College London
Sponsor type
University
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 50 Years
Official registry ID
NCT03093064
Official title
Show the full official title

The Role of Inflammation in Brain and Cognitive Function in Mental Disorders

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

London

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is King's College London, a university.

Did this study involve medication?

Yes. The study involved medication, including Natalizumab.

Who was this study for?

Listed age limits: 18 years to 50 years.

Want to explore more studies?

Explore studies